Aprepitant

Definition

Aprepitant is a selective neurokinin-1 (NK1) receptor antagonist primarily used to prevent nausea and vomiting associated with chemotherapy. By blocking the action of substance P, a neurotransmitter linked to these symptoms, aprepitant enhances the effectiveness of antiemetic therapy during cancer treatment.

5 Must Know Facts For Your Next Test

1. Aprepitant is often used in combination with other antiemetics, such as 5-HT3 receptor antagonists and corticosteroids, for enhanced anti-nausea effects.
2. It is administered orally and has a long half-life, allowing for a single dose to provide protection from nausea for several days following chemotherapy.
3. Common side effects of aprepitant may include fatigue, dizziness, and gastrointestinal disturbances like diarrhea.
4. Aprepitant is primarily metabolized by the liver enzyme CYP3A4, which can lead to drug interactions with other medications that are substrates of this enzyme.
5. The introduction of aprepitant has significantly improved the quality of life for patients undergoing chemotherapy by reducing the incidence of chemotherapy-induced nausea and vomiting (CINV).

Review Questions

• How does aprepitant function in preventing chemotherapy-induced nausea and vomiting?
  • Aprepitant works by selectively antagonizing the neurokinin-1 (NK1) receptors in the brain, which are activated by substance P. When these receptors are blocked, it reduces the signals that trigger nausea and vomiting during chemotherapy. This action is particularly important because many cancer treatments can cause severe nausea, and effectively managing this symptom can significantly improve a patient's overall treatment experience.
• Discuss the importance of combining aprepitant with other antiemetics in the management of chemotherapy-induced nausea and vomiting.
  • Combining aprepitant with other antiemetics, such as 5-HT3 receptor antagonists and corticosteroids, enhances its efficacy in preventing chemotherapy-induced nausea and vomiting. Each class of medication targets different pathways involved in the vomiting reflex. This multi-modal approach increases the chances of successful management of symptoms, leading to better patient outcomes and improved quality of life during cancer treatment.
• Evaluate the impact of aprepitant on patient outcomes in chemotherapy regimens compared to traditional antiemetic therapies.
  • The introduction of aprepitant has markedly changed patient outcomes in chemotherapy regimens by significantly reducing the incidence of acute and delayed chemotherapy-induced nausea and vomiting. Unlike traditional therapies that may have provided limited relief, aprepitant offers a targeted mechanism that works alongside other medications for comprehensive symptom control. As a result, patients experience fewer disruptions during their treatment cycles, leading to higher rates of treatment adherence and overall satisfaction with their cancer care.

Related terms

Chemotherapy: A treatment method that uses powerful chemicals to kill or slow the growth of cancer cells.

Antiemetics: Medications that help prevent or treat nausea and vomiting, especially during chemotherapy.

Substance P: A neuropeptide that plays a key role in transmitting pain and is involved in the vomiting reflex.